The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab

Jiang Liu; Deyu Gao; Jiaheng Li; Guangyin Hu; Jianhua Liu; Degan Liu

doi:10.2147/OTT.S382967

The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab

Onco Targets Ther. 2022 Oct 10:15:1161-1170. doi: 10.2147/OTT.S382967. eCollection 2022.

Authors

Jiang Liu^#¹, Deyu Gao², Jiaheng Li³, Guangyin Hu¹, Jianhua Liu¹, Degan Liu^#¹

Affiliations

¹ The Affiliated Xinghua People's Hospital, Medical School of Yangzhou University, Xinghua, People's Republic of China.
² Department of Laboratory Medicine, Hefei BOE Hospital, Hefei, People's Republic of China.
³ Clinical Laboratory of Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.

^# Contributed equally.

Abstract

Objective: Systemic inflammatory factors are independent risk factors in the formation and progression of various solid tumors. However, whether systemic inflammatory factors are associated with effect and prognosis of esophageal squamous cell carcinoma patients treated with immunotherapy remains unknown. The aim of this study is to assess the value of systemic inflammatory factors in the efficacy of camrelizumab for patients with advanced, metastatic esophageal squamous cell carcinoma.

Methods: We conducted a retrospective analysis of 90 patients with advanced, metastatic esophageal squamous cell carcinoma who received treatment with camrelizumab in Xinghua People's Hospital between August 2019 and October 2021. The optimal cut-off values of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) for predicting efficacy and prognosis were identified based on the receiver operating characteristic (ROC) curve. Progression free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and differences in PFS or OS between groups were compared by the Log rank test. Univariate and multivariate Cox proportional hazards regression models were performed to analyze prognostic values of each variable.

Results: The optimal cutoff values of PLR, NLR and SII predicted survival outcomes were 157.7, 3.84 and 750.8, respectively. Higher PLR, NLR and SII were associated with shorter PFS (HR for PLR = 2.899, P = 0.001; HR for NLR = 3.629, P < 0.001; HR for SII = 10.251, P < 0.001) and OS (HR for PLR = 4.583, P < 0.001; HR for NLR = 3.921, P < 0.001; HR for SII = 38.606, P < 0.001). Multivariate Cox regression analysis revealed that high PLR, NLR and SII were independent risk factors of PFS and OS in the advanced, metastatic esophageal squamous cell carcinoma patients receiving camrelizumab.

Conclusion: PLR, NLR and SII are potentially effective prognostic predictors in advanced, metastatic esophageal squamous cell carcinoma patients treated with camrelizumab.

Keywords: esophageal cancer; immunotherapy; prognostic predictors.